Chất ức chế kinase tyrosine

Strategic Sequencing of Systemic Therapies in Advanced Hepatocellular Carcinoma: Beyond the Second Line

By MedXY 06/28/2026

This article reviews evolving therapeutic sequences in advanced hepatocellular carcinoma, highlighting the integration of immune-based combinations, tyrosine kinase inhibitors, liver function preservation, and the emerging multidimensional CUSE framework to optimize patient outcomes beyond second-line treatment.

Hematology-Oncology news

Unraveling Molecular Mechanisms in Chronic Myeloid Leukemia: Insights from the EURO-SKI Biomarker Study on Treatment-Free Remission and Relapse

By MedXY 06/25/2026

The EURO-SKI Biomarker Study elucidates molecular signatures and immune interactions underlying treatment-free remission and relapse in chronic myeloid leukemia patients discontinuing tyrosine kinase inhibitors, highlighting immune communication as key to sustained remission.

Clinical Updates Hematology-Oncology news

Optimizing CML Management: Clinical Synthesis of the ASC4OPT Study and the Allosteric Inhibition Paradigm

By MedXY 04/27/2026

This review synthesizes the ASC4OPT trial results alongside pivotal evidence from the ASCEMBL and ASC4FIRST studies, evaluating the role of the STAMP inhibitor asciminib in chronic myeloid leukemia across multiple treatment lines.

Clinical Updates Hematology-Oncology news

Ribosome Collisions and the ZAK-Dependent Ribotoxic Stress Response: A Novel Therapeutic Vulnerability in Chronic Myeloid Leukemia

By MedXY 04/03/2026

This review synthesizes evidence that BCR::ABL1 inhibitors induce ribosome collisions and ZAK-dependent apoptosis, highlighting the ribotoxic stress response as a critical pathway for TKI efficacy and a potential target to overcome resistance in CML progression.